Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

NCT: NCT05674240 · COMPLETED

NCT IDNCT05674240
StatusCOMPLETED
Start Date2022-12-06
Completion2026-03-20

Brief Summary

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

Frequently Asked Questions

What is Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain?

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain is a clinical trial registered under NCT05674240. Current status: COMPLETED.

What is the status of NCT05674240?

The current status of NCT05674240 (Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain) is: COMPLETED.

When did Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain start?

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain started on 2022-12-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑